Policy of Making the Tissue Culture and Cell Processing Businesses Core Growth Areas
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「With the regenerative medicine market expected to expand, the company positions the tissue culture and cell processing businesses, which support that market, as core growth businesses and will implement priority strategies.」
The company continues to pursue its policy of making the tissue culture and cell processing businesses the core of growth. - FY2025RestatedAnnual report
「With the regenerative medicine market expected to expand, the company positions the tissue culture and cell processing businesses, which support that market, as core growth businesses and will implement priority strategies.」
The company has reiterated its policy of making the tissue culture and cell processing businesses the core of growth. - FY2024First statedAnnual report
「With the regenerative medicine market expected to expand, the company positions the tissue culture and cell processing businesses, which support that market, as core growth businesses and will implement priority strategies.」
Against the backdrop of growth in the regenerative medicine market, the company has designated the two businesses as priority areas.